In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...

(MENAFN- GlobeNewsWire - Nasdaq) The ocular hypertension market is growing due to the rising prevalence of conditions impairing aqueous humor outflow, such as scarring and inflammation, leading to ...

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase ...

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastrointestinal Tumor. According to GlobalData, Phase II drugs for Gastrointestinal Tumor does not have ...

Ten years ago, in 2014, Baili Pharmaceutical founded SystImmune in Seattle, USA, and began to develop the first-in-class EGFR × HER3 bispecific antibody ADC (BL-B01D1). In 2024, Baili Pharmaceutical ...

New York, USA, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Advancements in Ocular Hypertension Clinical Trial Pipeline as 60+ Companies Pave the Way for Future Solutions | DelveInsight The ocular ...

New York, USA, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Advancements in Ocular Hypertension Clinical Trial Pipeline as 60+ Companies Pave the Way for Future Solutions | DelveInsight The ocular hypertension ...

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.